Imatinib Stada (Imatinib)

Imatinib is a targeted therapy that inhibits specific tyrosine kinases involved in several hematologic and solid tumours.

• Chronic myeloid leukemia (CML): reduces malignant cell proliferation and achieves durable hematologic and cytogenetic responses.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission by blocking BCR‑ABL signaling.
• Gastrointestinal stromal tumor (GIST): limits tumor growth by inhibiting c‑KIT and PDGFR pathways.

• Imatinib selectively binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and platelet‑derived growth factor receptor (PDGFR) tyrosine kinases, preventing their phosphorylation. This blockade halts downstream signaling cascades that drive uncontrolled cell division and survival, leading to apoptosis of malignant cells while sparing most normal tissues.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, often transient.
• Edema: swelling of the ankles or hands.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiotoxicity: reduced left ventricular function or heart failure.
• Severe neutropenia: marked drop in neutrophil count increasing infection risk.

When prescribing Imatinib, clinicians should consider several safety precautions to minimize risks.

• Baseline liver function: assess hepatic enzymes before initiating therapy.
• Cardiac monitoring: evaluate left ventricular ejection fraction in patients with cardiac history.
• Hematologic surveillance: perform regular complete blood counts to detect cytopenias.
• Drug interactions: review concomitant medications that affect CYP3A4 metabolism.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce Imatinib exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase Imatinib levels and risk of toxicity.
• Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• CYP2C8 substrates (e.g., paclitaxel): may have altered metabolism.
• P‑gp inhibitors (e.g., verapamil): can raise Imatinib concentrations modestly.
• Warfarin: monitor INR as Imatinib may affect anticoagulation.